['type 2 diabetes mellitus']
['dapagliflozin 10 mg', 'matching placebo for dapagliflozin']

        Inclusion Criteria:

          -  Female or male aged ≥18 years and <75 years.

          -  History of T2DM for more than 12 months.

          -  Inadequate glycemic control, defined as HbA1c ≥7.0% and ≤11%

          -  Stable anti-diabetic treatment regimen

          -  Renal impairment: CKD 3A

        Exclusion Criteria:

          -  Women of childbearing potential who are unwilling or unable to use an acceptable
             method to avoid pregnancy for the entire study period.

          -  History of diabetic ketoacidosis or hyperosmolar nonketotic coma.

          -  Severe uncontrolled hypertension defined as SBP ≥180 mmHg and/or Diastolic Blood
             Pressure (DBP) ≥110 mmHg

          -  Any of the following Cardiovascular (CV)/Vascular Diseases within 3 months of prior to
             signing the consent at visit 1:

        Myocardial infarction, Cardiac surgery or revascularization(CABG/PTCA), Unstable angina,
        Unstable heart failure (HF), HF New York Heart Association (NYHA) Class IV,Transient
        ischemic attack (TIA) or significant cerebrovascular disease, Unstable or previously
        undiagnosed arrhythmia.

          -  History of any biopsy or imaging verifying intercurrent kidney disease (such as
             glomerular nephritis or sign of renal artery stenosis) other than diabetic nephropathy
             or diabetic nephropathy with nephrosclerosis.

          -  Significant hepatic disease, including, but not limited to, chronic active hepatitis
             and/or severe hepatic insufficiency.

          -  Ongoing treatment with any SGLT2-inhibitor, GLP-1 analogue, or rapid/short acting
             insulins at screening.

          -  Participation in another clinical study with an Investigational Product (IP) during
             the last 30 days prior to signing the consent at visit 1.
      